Impact of weight loss on the metabolic syndrome

• Published in: International Journal of Obesity 2007-09, Vol.31 (9), p.1442-1448
• Main Authors: Phelan, S, Wadden, T.A, Berkowitz, R.I, Sarwer, D.B, Womble, L.G, Cato, R.K, Rothman, R
• Format: Article
• Language: English
• Subjects: Adult; African Americans; Aged; Appetite Depressants - therapeutic use; Biological and medical sciences; Body mass index; Cardiovascular disease; Cardiovascular diseases; Counseling; Cyclobutanes - therapeutic use; Diabetes; diet counseling; diet therapy; disease prevalence; Dosage and administration; Drug therapy; epidemiological studies; Epidemiology; Ethnicity; Feeding. Feeding behavior; Female; Females; Fundamental and applied biological sciences. Psychology; gender differences; Health aspects; Health Promotion and Disease Prevention; Humans; Hypertension; Internal Medicine; Life Style; lifestyle; Lifestyles; long term effects; longitudinal studies; Male; Males; Medical sciences; Medicine; Medicine & Public Health; men; Metabolic Diseases; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - prevention & control; Metabolic syndrome X; Middle Aged; middle-aged adults; Minority & ethnic groups; Miscellaneous; Obesity; Obesity - therapy; original-article; Other metabolic disorders; physiological response; Primary care; Public Health; randomized clinical trials; remission; Risk factors; Sibutramine; Treatment Outcome; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Weight control; Weight loss; Weight Loss - drug effects; Whites; women; young adults
• ISSN: 0307-0565; 1476-5497
• DOI: 10.1038/sj.ijo.0803606

Objective: To evaluate the effects of weight loss on the risk of having metabolic syndrome after 1 year of treatment with lifestyle modification alone, pharmacotherapy alone (sibutramine) or the combination of the two. Design: Randomized, controlled, 1-year clinical trial. Patients: One hundred and eighty women and 44 men, 18-65 years of age, with a body mass index of 30-45 kg/m2, free of uncontrolled hypertension or type 1 or 2 diabetes. Intervention: Fifteen milligrams of sibutramine per day alone, lifestyle modification counseling alone, sibutramine plus lifestyle modification counseling or sibutramine plus brief lifestyle modification counseling. Measurements: The metabolic syndrome, as defined by the Adult Treatment Panel III. Results: Before treatment, 34.8% of the participants had the metabolic syndrome. Metabolic syndrome was more prevalent in Caucasians than African Americans (42.5 vs 20.3%; P